Evidence map›Paper›PMID 41864890›Full record

ArticleBMC immunology2026

Proteome-wide autoantibody screening and holistic autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape.

Kazuki M Matsuda, Yoshiaki Kawase, Kazuhiro Iwadoh, Makoto Kurano, Yutaka Yatomi, Koh Okamoto, Kyoji Moriya, Hirohito Kotani, Teruyoshi Hisamoto, Ai Kuzumi and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Kazuki M Matsuda *Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan. matsudak-der@h.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-8194-9140
Yoshiaki Kawase *Department of Computer Science, The University of Tokyo Graduate School of Information Science and Technology, Tokyo, Japan.
Kazuhiro IwadohDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Makoto KuranoDepartment of Clinical Laboratory Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Yutaka YatomiGraduate School, International University of Health and Welfare, Tokyo, Japan.
Koh OkamotoDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Kyoji MoriyaDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Hirohito KotaniDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Teruyoshi HisamotoDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Ai KuzumiDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Takemichi FukasawaDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Asako Yoshizaki-OgawaDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Masanori KonoDepartment of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Tomohisa OkamuraDepartment of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Hirofumi ShodaDepartment of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Keishi FujioDepartment of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Kei YamaguchiProteoBridge Corporation, Tokyo, Japan.
Taishi OkumuraProteoBridge Corporation, Tokyo, Japan.
Chihiro OnoProteoBridge Corporation, Tokyo, Japan.
Yuki KobayashiProteoBridge Corporation, Tokyo, Japan.
Ayaka SatoProteoBridge Corporation, Tokyo, Japan.
Ayako MiyaProteoBridge Corporation, Tokyo, Japan.
Rikako UchinoNOV Academic Research, TOKIWA Pharmaceutical Co., Ltd., Tokyo, Japan.
Yumi MurakamiNOV Academic Research, TOKIWA Pharmaceutical Co., Ltd., Tokyo, Japan.
Hiroshi MatsunakaNOV Academic Research, TOKIWA Pharmaceutical Co., Ltd., Tokyo, Japan.
Hiroshi ImaiDepartment of Computer Science, The University of Tokyo Graduate School of Information Science and Technology, Tokyo, Japan.
Shinichi SatoDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Rudy RaymondDepartment of Computer Science, The University of Tokyo Graduate School of Information Science and Technology, Tokyo, Japan.
Ayumi YoshizakiDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Naoki GoshimaProteoBridge Corporation, Tokyo, Japan.

Funding

Japan Society for the Promotion of Science 23K19607, 25K19589, 25HP8021TOKIWA Pharmaceuticals Co., Ltd. Joint research funding
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AutoantibodyAutoantigenomicsCOVID-19Proteome-wide autoantibody screeningWet protein array

Identifiers

PMID41864890
PMCPMC13321555

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.